Cargando…

Cardiac Phenotype of Prehypertrophic Fabry Disease

BACKGROUND: Fabry disease (FD) is a rare and treatable X-linked lysosomal storage disorder. Cardiac involvement determines outcomes; therefore, detecting early changes is important. Native T1 by cardiovascular magnetic resonance is low, reflecting sphingolipid storage. Early phenotype development is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nordin, Sabrina, Kozor, Rebecca, Baig, Shanat, Abdel-Gadir, Amna, Medina-Menacho, Katia, Rosmini, Stefania, Captur, Gabriella, Tchan, Michel, Geberhiwot, Tarekegn, Murphy, Elaine, Lachmann, Robin, Ramaswami, Uma, Edwards, Nicola C., Hughes, Derralynn, Steeds, Richard P., Moon, James C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023585/ https://www.ncbi.nlm.nih.gov/pubmed/29853467 http://dx.doi.org/10.1161/CIRCIMAGING.117.007168

Ejemplares similares

Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy
por: Nordin, Sabrina, et al.
Publicado: (2019)

Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage
por: Augusto, João B, et al.
Publicado: (2020)

A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
por: Kozor, Rebecca, et al.
Publicado: (2016)

Fabry disease and incidence of cancer
por: Bird, Sarah, et al.
Publicado: (2017)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Atherosclerosis in Fabry Disease—A Contemporary Review
por: Roy, Ashwin, et al.
Publicado: (2021)

Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2022)

Systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in Fabry disease
por: Vijapurapu, Ravi, et al.
Publicado: (2023)

Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial
por: Baig, Shanat, et al.
Publicado: (2018)

Prospective cardiovascular magnetic resonance imaging in adults with Alström syndrome: silent progression of diffuse interstitial fibrosis
por: Baig, Shanat, et al.
Publicado: (2020)

Progressive cardiac involvement in a compound heterozygote Fabry patient: a case report
por: McConnell, Eliza Jeanette, et al.
Publicado: (2018)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Increased cardiac involvement in Fabry disease using blood-corrected native T1 mapping
por: Nickander, Jannike, et al.
Publicado: (2023)

Update on role of agalsidase alfa in management of Fabry disease
por: Ramaswami, Uma
Publicado: (2011)

Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance
por: Geberhiwot, Tarekegn, et al.
Publicado: (2021)

A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease
por: Kozor, Rebecca, et al.
Publicado: (2015)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel
por: Stepien, Karolina M., et al.
Publicado: (2023)

Reproducibility of native T1 mapping using ShMOLLI and MOLLI - implications for sample size calculation
por: Bhuva, Anish N, et al.
Publicado: (2016)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

The Right ventricle and cardiac surgery - more resilient than thought: multiparametric quantification shows altered rather than reduced function
por: Medina, Katia D Menacho, et al.
Publicado: (2016)

The Paracrine Feedback Loop Between Vitamin D(3) (1,25(OH)(2)D(3)) and PTHrP in Prehypertrophic Chondrocytes
por: Bach, Frances C, et al.
Publicado: (2014)

Early effects of kidney transplantation on the heart - A cardiac magnetic resonance multi-parametric study()
por: Hayer, Manvir K., et al.
Publicado: (2019)

Translation of quality of life scale for pediatric patients with Fabry disease in Japan
por: Koto, Yuta, et al.
Publicado: (2022)

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)
por: Ramaswami, Uma, et al.
Publicado: (2012)

REWIND Diabetes for Octogenarians
por: Geberhiwot, Tarekegn
Publicado: (2021)

Alström syndrome: a paradigm for diffuse fibrosis and clinical progression
por: Edwards, Nicola C, et al.
Publicado: (2013)

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
por: Beck, Michael, et al.
Publicado: (2022)

Clinical application of MOLLI T1* for extracellular volume calculation in healthy volunteers and aortic stenosis
por: Bhuva, Anish N, et al.
Publicado: (2015)

Paediatric Fabry disease: prognostic significance of ocular changes for disease severity
por: Kalkum, Gisela, et al.
Publicado: (2016)

INCA (Peru) Study: Impact of Non‐Invasive Cardiac Magnetic Resonance Assessment in the Developing World
por: Menacho, Katia, et al.
Publicado: (2018)

Performance of automated ECV maps versus conventionally calculated ECV
por: Rosmini, Stefania, et al.
Publicado: (2015)

Native T1 lowering in iron overload and Anderson Fabry disease; a novel and early marker of disease
por: Sado, Daniel, et al.
Publicado: (2013)

Impact of SARS‐CoV‐2 (COVID‐19) pandemic on patients with lysosomal storage disorders and restoration of services: experience from a specialist centre
por: Ramaswami, Uma, et al.
Publicado: (2021)

Clinical prodromes of neurodegeneration in Anderson-Fabry disease
por: Löhle, Matthias, et al.
Publicado: (2015)

Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England
por: Cleary, Maureen, et al.
Publicado: (2021)

Redefining viability by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction
por: Bulluck, Heerajnarain, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fe6fr8fhbp40pjs0504nprv8cq